(Nasdaq: CODX) ("Co-Dx" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today highlighted capabilities of its ...
Five-year forecasts by application, technology, product and setting, from clinical labs to point of care, as syndromic multiplex panels reshape molecular diagnostics after the pandemic.Dublin, Oct. 08 ...
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its ...
HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company has ...
Blood-based testing could open new markets for the Co-Dx® PCR platform, including HIV and hepatitis B and C. Co-Diagnostics and ReadyGo target decentralized Ebola detection as th ...
Polymerase chain reaction (PCR) tests are one of the most popular diagnostic tools for the detection and diagnosis of viral diseases, such as coronavirus (COVID-19), due to their ability to rapidly ...
Co-Diagnostics, Inc. announced its upcoming participation at WHX Labs Johannesburg, taking place October 6-8, 2026, at the Gallagher Convention Centre in Johannesburg, South Africa. Attendees are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results